Most NAFLD patients are obese and present a mild systemic inflammation, which hampers insulin signaling [insulin resistance (IR)], playing a relevant role in the pathomechanism of liver damage (7, 8). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.